Axsome

Pharma

Axsome increases Auvelity's peak sales projection to $8B

A few days after gaining an FDA expansion for Auvelity to treat Alzheimer’s disease agitation, Axsome has projected its peak sales to reach $8 billion.

Kevin Dunleavy May 5, 2026 11:48am

Axsome's Auvelity wins FDA expansion for Alzheimer's agitation

May 1, 2026 11:42am

Fierce Biotech

FDA refuses Axsome filing for former Pfizer fibromyalgia asset

Jun 9, 2025 12:27pm

diversity in clinical trials clinical trial study research healthcare doctor patient

Axsome will begin trial this year in MDD with daytime sleepiness

Apr 1, 2025 4:40pm

Axsome's Sunosi scores in phase 3 ADHD trial

Mar 25, 2025 11:46am

Teva agrees with Axsome to keep generic off market until 2038

Feb 10, 2025 11:28am